We back ambitious founders across the UK and Ireland that are turning breakthrough ideas into world-leading businesses in deep tech and life sciences. We bring deep domain expertise, alongside scaling support, from a platform that few early-stage investors can match.
What we do
We make initial investments of £3m-£10m, focused on deep tech and life sciences companies that meet the following criteria:
- Headquartered in the UK or Ireland
- Seeking funding from late seed to series B
- Possess compelling, validated technology, with a clear value proposition
- Underpinned by strong market drivers and early commercial traction
Life sciences
We’re helping to turn world-class research and scientific discovery into meaningful patient outcomes. So far, we’ve deployed £160m+ across our focus areas of:
- Drug Discovery & Development
- MedTech
- Diagnostics
- Advanced Tools & Materials
Deep tech
We back pioneering technologies, grounded in scientific and engineering excellence, to enable the next generation of global disruptors. We’ve invested £110m+ across our focus areas of:
- Semiconductors & Photonics
- Advanced Materials
- AI & Software Platforms
- Energy Storage & Management
- Energy & Resource Efficiency
Accelerating impact
Our Early Stage team members in London, Cambridge, and across the UK bring together deep domain knowledge, venture capital experience, and commercial insight. Since 2019, they’ve built a track record of scaling science-led innovation into global success:
- £270m+ investment deployed
- 60+ high-growth companies backed
- 130+ transactions completed
How we’re different
We’re uniquely equipped to provide venture capital investment, with the reach and resources of a private equity platform:
Domain expertise
Deep technical and commercial expertise, across PhDs, MBAs and experience in VC, consulting, banking and tech
Scaling support
A dedicated team to support your go-to-market strategy, product-market fit, talent mapping, and more
Track record
Built on a foundation of 600+ investments and 200+ exits, across the full BGF portfolio
Patient capital
Evergreen fund structure that’s been purpose-built to support long-term growth
Meet the team
-
• Leadership
Tim Rea
Co-Head of Early Stage
-
• Leadership
Dennis Atkinson
Co-Head of Early Stage
-
• Early Stage
Lucy Edwardes Jones
Investor
-
• Early Stage
Kate Ronayne
Investor
-
• Early Stage
Rowan Bird
Investor
-
• Early Stage
Maggy Lau
Investor
-
• Early Stage
Freddie Mitchell
Investor
-
• Early Stage
Katharine Cooper
Executive Assistant
-
• Early Stage
Talia Hoffman
Portfolio
-
• Early Stage
Luke Rajah
Partner, Portfolio
-
• Leadership
Ben Barker
Head of Portfolio
Introduce yourself
If you’re looking for an investment partner that can provide patient, flexible capital and scaling support, alongside deep technical and commercial expertise, we could be a great fit. See if you meet our criteria and apply for funding today.
